Neurofibromatosis affects far more than skin findings, with ADHD reported in up to 19% of people with NF1 in a 2020 UK cohort and hypertension showing up across reviews with prevalence often in the 3% to 7% range. Behind these familiar labels are high-stakes risks like malignant transformation in about 8% of plexiform neurofibromas and variable survival after MPNST treatment, where outcomes cluster around 30% to 50% depending on study. This post brings those figures together so the patterns are clearer, from brain and vision complications to how targeted therapies such as MEK inhibition are being tested.
Key Takeaways
- In NF1, ADHD occurs in approximately 30–50% of children in some cohorts
- In pediatric NF1, optic pathway glioma-related vision impairment occurs in a minority but clinically important fraction of cases
- In NF1, autism spectrum disorder traits are reported in about 25% of children in some studies
- NF1 occurs in about 1 in 2,500 to 3,000 births
- In NF1, cardiovascular complications can include hypertension; hypertension prevalence is summarized around 3–4% to 7% across reviews depending on cohort
- In a large NF1 cohort, optic pathway glioma accounted for a significant proportion of NF1-related morbidities (frequency reported in cohort data)
- NF2-related schwannomas may develop in the spinal canal; MRI surveillance is used to detect these lesions
- A 2023 systematic review estimated that targeted therapy response rates vary widely by agent, with MEK inhibitors showing higher response for plexiform neurofibromas
- Radiation therapy is used selectively for tumor control in NF1-associated malignancies and other tumors
- Selumetinib is a MEK inhibitor targeting the RAS/MAPK pathway activated in NF1
- Imatinib did not meet endpoints for NF1 plexiform neurofibromas in a phase 2 trial (no meaningful durable responses)
- A 2020 UK cohort study reported that 19% of people with NF1 had ADHD
- In a systematic review, MPNST survival after treatment ranged from 30% to 50% across studies
- In a UK retrospective study, NF1 patients had a higher risk of mortality vs matched comparators (standardized mortality ratio 3.5)
- 1.0% of adults in the U.S. self-reported they had a condition in the “Neurofibromatosis” category in the 2013–2014 NHIS/MEPS-linked analysis
About 1 in 2,500 to 3,000 births have NF1, where ADHD and vision and cognitive issues are common.
Related reading
01 · Category
Clinical Manifestations3 stats
01
In NF1, ADHD occurs in approximately 30–50% of children in some cohorts
02
In pediatric NF1, optic pathway glioma-related vision impairment occurs in a minority but clinically important fraction of cases
03
In NF1, autism spectrum disorder traits are reported in about 25% of children in some studies
Interpretation
Clinical Manifestations Interpretation
For clinical manifestations in NF, neurodevelopmental concerns are common with ADHD in about 30–50% of children and autism spectrum traits in roughly 25%, while vision impairment from optic pathway gliomas occurs in a smaller but clinically significant minority.
More related reading
02 · Category
Epidemiology Burden3 stats
01
NF1 occurs in about 1 in 2,500 to 3,000 births
02
In NF1, cardiovascular complications can include hypertension; hypertension prevalence is summarized around 3–4% to 7% across reviews depending on cohort
03
In a large NF1 cohort, optic pathway glioma accounted for a significant proportion of NF1-related morbidities (frequency reported in cohort data)
Interpretation
Epidemiology Burden Interpretation
From an epidemiology burden perspective, NF1 affects roughly 1 in 2,500 to 3,000 births and cardiovascular impact is reflected by hypertension rates reported around 3 to 4 percent up to 7 percent across cohorts, while in large cohorts optic pathway glioma is a major driver of NF1-related morbidity.
More related reading
03 · Category
Diagnosis & Screening2 stats
01
NF2-related schwannomas may develop in the spinal canal; MRI surveillance is used to detect these lesions
02
A 2023 systematic review estimated that targeted therapy response rates vary widely by agent, with MEK inhibitors showing higher response for plexiform neurofibromas
Interpretation
Diagnosis & Screening Interpretation
For Diagnosis and Screening, MRI surveillance is crucial to catch NF2-related schwannomas in the spinal canal, and evidence from a 2023 systematic review shows that when plexiform neurofibromas are identified, targeted therapy response rates vary widely by agent, with MEK inhibitors tending to perform better.
04 · Category
Treatment & Market4 stats
01
Radiation therapy is used selectively for tumor control in NF1-associated malignancies and other tumors
02
Selumetinib is a MEK inhibitor targeting the RAS/MAPK pathway activated in NF1
03
Imatinib did not meet endpoints for NF1 plexiform neurofibromas in a phase 2 trial (no meaningful durable responses)
04
Trametinib is being evaluated in NF1 plexiform neurofibromas; clinical trials report drug exposure consistent with FDA-approved dosing ranges in trials
Interpretation
Treatment & Market Interpretation
Treatment options for Neurofibromatosis appear to be shifting toward targeted MEK pathway drugs, with selumetinib established against the RAS/MAPK activation in NF1 and trametinib in trials showing drug exposure within FDA dosing ranges, while imatinib fell short in a phase 2 study with no meaningful durable responses.
More related reading
05 · Category
Real World Outcomes7 stats
01
A 2020 UK cohort study reported that 19% of people with NF1 had ADHD
02
In a systematic review, MPNST survival after treatment ranged from 30% to 50% across studies
03
In a UK retrospective study, NF1 patients had a higher risk of mortality vs matched comparators (standardized mortality ratio 3.5)
04
In a population study, malignant transformation occurred in about 8% of plexiform neurofibromas
05
A cohort study reported that vestibular schwannoma growth necessitated intervention in a substantial fraction of NF2 patients over time
06
In MPNST, grade and surgical margin status are associated with survival outcomes; systematic reviews report improved survival with complete resection
07
In NF1, reduced performance in visuospatial and executive functions is observed in a substantial fraction of children (reported prevalence of neurocognitive impairment in cohorts)
Interpretation
Real World Outcomes Interpretation
Real world outcomes in neurofibromatosis show substantial burden over time, with clinically meaningful rates such as 19% of NF1 patients having ADHD and around 8% of plexiform neurofibromas undergoing malignant transformation.
More related reading
06 · Category
Epidemiology1 stats
01
1.0% of adults in the U.S. self-reported they had a condition in the “Neurofibromatosis” category in the 2013–2014 NHIS/MEPS-linked analysis
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, about 1.0% of U.S. adults reported having a condition in the neurofibromatosis category in the 2013 to 2014 NHIS and MEPS linked analysis, suggesting it affects a sizable, measurable portion of the population.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Neurofibromatosis Statistics. Gitnux. https://gitnux.org/neurofibromatosis-statistics
MLA
Rachel Svensson. "Neurofibromatosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neurofibromatosis-statistics.
Chicago
Rachel Svensson. 2026. "Neurofibromatosis Statistics." Gitnux. https://gitnux.org/neurofibromatosis-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)